Phase 3 Study of KHK7580

NCT02549391 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

634

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: KHK7580
DRUG: KRN1493

Sponsor

Kyowa Kirin Co., Ltd.